Device Trial Radar · NCT05713019
ATP and P2X3 Receptor in Chronic Cough
Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 28, 2023
Primary completion
Mar 28, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Imperial College LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a laboratory-based study that will be performed at the Clinical Research Centre at the Royal Brompton Hospital,London. The objectives are: 1. Determine whether adenosine triphosphate (ATP) is present or released in airways of idiopathic chronic cough patients 2. Determine whether there is an increase in cough sensitivity and laryngeal sensitivity to exogenous ATP 3. Examine the effects of exogenous ATP on the inflammatory response in the upper and lower airways. The participants will be: (i) Healthy subjects: non-smoker (8 subjects) and (ii) Chronic cough subjects attending Chronic Cough clinic (12 subjects). Each will be involved in: Study 1. Following recruitment, subjects will attend for a fiberoptic bronchoscopy. Study 2: Subjects will take part in a study of the effect of inhaling nebulized ATP. Subjects will be studied on 2 days separated by at least 5 days. On each day, after measurements of lung function, FeNO and cough questionnaires, the subject will inhale either saline or ATP solution from a nebulizer, following which laryngeal hypersensitivity, capsaicin cough challenge and sputum induction will be performed. Results will be expressed as mean ± standard error of the mean (SEM). Study data will be analysed by the Investigators at the completion of the study. Planned analyses will be done by comparing chronic cough patients to the healthy controls. The Spearman rank-correlation test will be used to determine correlations.
Conditions
- Cough
Interventions
Adenosine triphosphate (ATP) solution inhalation from nebuliserDevice
ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
Inhalational challenge with increasing concentrations of capsaicin solutionsDiagnostic test
Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
Recording of Cough Count and frequency using the Hyfe Cough MonitorDevice
All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to "wear" the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table. Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded.
Collection of exhaled breath condensateProcedure
EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
Continuous laryngoscopic examinationDiagnostic test
Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
Sputum inductionDiagnostic test
Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped. Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained.
Spirometric measurementsDiagnostic test
Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
Blood sample collectionDiagnostic test
Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Does ATP inhalation compared to that of saline inhalation change capsaicin cough sensitivity and laryngeal sensitivity?Time frame: 18 months
- Compare the levels of ATP in bronchoalveolar lavage fluid and in exhaled breath condensate from chronic cough patients to those of non-coughing healthy subjectsTime frame: 18 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.